CVD ancillary study, was involved in the CT data collection, and provided critical revisions to the paper. Dr. Budoff interpreted the cardiac CT scans for the study (CT Core Lab) and provided critical revisions to the paper. Dr. Otvos provided the GlycA measurements and provided critical revisions to the paper. Drs. Zhao, Brown, Guallar, Palella, Martinson, Akinkuolie, Haberlen, and Mora provided critical revisions to the paper. Dr. Michos, Fashanu, and Tibuakuu take full responsibility for its content. All authors reviewed the final draft and approve of its submission. The manuscript was also approved by the MACS Executive Committee. Disclosures: Dr. Brown has served as a consultant to Gilead Sciences, Merck, BMS, EMD-Serono, and Theratechnologies. Dr. Budoff has received research funds from GE Healthcare. Dr. Otvos is employed by LabCorp (formally LipoScence). Dr. Mora has received research grant support from Atherotech Diagnostics, and has received consulting fees from Quest Diagnostics for work outside the current study. Dr. Mora has a patent application on the use of GlycA for predicting risk of colorectal cancer. No other authors report any conflicts.